• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Thursday's After-Market Session

    5/2/24 4:31:10 PM ET
    $ALLR
    $APVO
    $ARDX
    $CRDF
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ALLR alert in real time by email

    Gainers

    • Twist Bioscience (NASDAQ:TWST) stock increased by 14.1% to $36.51 during Thursday's after-market session. The company's market cap stands at $2.1 billion. The company's, Q2 earnings came out today.
    • Jaguar Health (NASDAQ:JAGX) shares increased by 13.91% to $0.33. The company's market cap stands at $95.9 million.
    • Tandem Diabetes Care (NASDAQ:TNDM) stock moved upwards by 12.25% to $41.04. The market value of their outstanding shares is at $2.6 billion. As per the press release, Q1 earnings came out today.
    • Indaptus Therapeutics (NASDAQ:INDP) stock moved upwards by 11.29% to $2.26. The company's market cap stands at $19.2 million.
    • Ardelyx (NASDAQ:ARDX) shares rose 11.02% to $7.54. The company's market cap stands at $1.7 billion. As per the news, the Q1 earnings report came out today.
    • NKGen Biotech (NASDAQ:NKGN) shares rose 8.33% to $1.43. The market value of their outstanding shares is at $32.6 million.

    Losers

    • Cue Biopharma (NASDAQ:CUE) shares declined by 7.5% to $1.74 during Thursday's after-market session. The company's market cap stands at $84.6 million.
    • Cardiff Oncology (NASDAQ:CRDF) stock decreased by 6.7% to $4.18. The market value of their outstanding shares is at $186.8 million. The company's, Q1 earnings came out today.
    • Orchestra BioMed Hldgs (NASDAQ:OBIO) shares declined by 6.31% to $5.2. The market value of their outstanding shares is at $186.0 million.
    • Aptevo Therapeutics (NASDAQ:APVO) stock declined by 6.12% to $1.06. The company's market cap stands at $3.8 million.
    • Allarity Therapeutics (NASDAQ:ALLR) shares fell 5.7% to $1.16. The company's market cap stands at $2.2 million.
    • Varex Imaging (NASDAQ:VREX) shares decreased by 5.67% to $15.5. The market value of their outstanding shares is at $629.5 million. The company's, Q2 earnings came out today. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ALLR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ALLR
    $APVO
    $ARDX
    $CRDF

    CompanyDatePrice TargetRatingAnalyst
    Tandem Diabetes Care Inc.
    $TNDM
    3/19/2026$35.00Hold → Buy
    Truist
    Tandem Diabetes Care Inc.
    $TNDM
    3/17/2026$33.00Neutral → Overweight
    Piper Sandler
    Tandem Diabetes Care Inc.
    $TNDM
    2/23/2026$50.00Hold → Buy
    Lake Street
    Tandem Diabetes Care Inc.
    $TNDM
    2/20/2026$30.00Underperform → Neutral
    BofA Securities
    Tandem Diabetes Care Inc.
    $TNDM
    1/27/2026$25.00Buy
    TD Cowen
    Ardelyx Inc.
    $ARDX
    1/9/2026Neutral → Overweight
    Piper Sandler
    Cardiff Oncology Inc.
    $CRDF
    1/5/2026$12.00Outperform
    Noble Capital Markets
    Tandem Diabetes Care Inc.
    $TNDM
    12/16/2025$30.00Neutral → Outperform
    Robert W. Baird
    More analyst ratings

    $ALLR
    $APVO
    $ARDX
    $CRDF
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Officer Hochman David P bought $42,900 worth of shares (10,000 units at $4.29), increasing direct ownership by 0.93% to 1,086,467 units (SEC Form 4)

    4 - Orchestra BioMed Holdings, Inc. (0001814114) (Issuer)

    3/16/26 4:54:18 PM ET
    $OBIO
    Medicinal Chemicals and Botanical Products
    Health Care

    Director Mott David M bought $1,946,331 worth of shares (333,333 units at $5.84), increasing direct ownership by 11% to 3,302,918 units (SEC Form 4)

    4 - ARDELYX, INC. (0001437402) (Issuer)

    2/23/26 9:01:11 PM ET
    $ARDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Sarraf Pasha bought $99,747 worth of shares (323,857 units at $0.31) (SEC Form 4)

    4 - Cue Biopharma, Inc. (0001645460) (Issuer)

    1/2/26 4:00:03 PM ET
    $CUE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALLR
    $APVO
    $ARDX
    $CRDF
    SEC Filings

    View All

    SEC Form 10-K filed by Indaptus Therapeutics Inc.

    10-K - Indaptus Therapeutics, Inc. (0001857044) (Filer)

    3/17/26 4:30:44 PM ET
    $INDP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Twist Bioscience Corporation

    144 - Twist Bioscience Corp (0001581280) (Subject)

    3/17/26 2:17:02 PM ET
    $TWST
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form S-3 filed by Cue Biopharma Inc.

    S-3 - Cue Biopharma, Inc. (0001645460) (Filer)

    3/17/26 11:31:53 AM ET
    $CUE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALLR
    $APVO
    $ARDX
    $CRDF
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Cardiff Oncology to Present Preclinical Data with Highly Specific PLK1 Inhibitor Onvansertib at the 2026 AACR Annual Meeting

    SAN DIEGO, March 19, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that new preclinical data highlighting the potential of its highly specific oral PLK1 inhibitor, onvansertib, in combination with trastuzumab deruxtecan (T-DXd) will be presented at the American Association for Cancer Research Annual Meeting 2026, taking place April 17-22, 2026 in San Diego, California. The poster presentation will showcase findings demonstrating that onvansertib enhanced the antitumor activity of T-DXd and reversed resistance in therapy-resistant HER2-low

    3/19/26 7:00:00 AM ET
    $CRDF
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Cue Biopharma Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights

    Advanced research and development of CUE-401 for IND (Investigational New Drug) readiness –CUE-401 is the Company's lead asset for the treatment of autoimmune and inflammatory diseasesAppointed industry veteran Lucinda Warren as Chief Financial and Business OfficerRaised net proceeds of $10.2M through an underwritten public offeringAnnounced strategic collaboration and license agreement with ImmunoScape to develop breakthrough cell therapy approach for solid tumors – Entitled to receive upfront payments totaling $15M BOSTON, March 16, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ:CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to s

    3/16/26 4:05:00 PM ET
    $CUE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Varex Announces Successful Completion of Debt Refinancing

    Varex Imaging Corporation (NASDAQ:VREX) today announced it has entered into a Credit and Guaranty Agreement (the "Credit Agreement"), dated as of March 13, 2026, which includes a secured term loan facility in aggregate principal amount of $350 million, a secured revolving credit facility in aggregate principal amount of $100 million and a secured delayed draw term loan facility in aggregate principal amount of $40 million (collectively, the "Credit Facility"), providing for aggregate commitments of $490 million and maturing on March 13, 2031. Zions Bancorporation, N.A. ("Zions") acted as lead arranger and bookrunner for the new Credit Facility and will act as the administrative agent and co

    3/16/26 8:30:00 AM ET
    $VREX
    Industrial Machinery/Components
    Technology

    $ALLR
    $APVO
    $ARDX
    $CRDF
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    February 28, 2025 - FDA Roundup: February 28, 2025

    For Immediate Release: February 28, 2025 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:On Thursday, the FDA approved Odactra to include use in individuals 5 through 11 years of age to treat house dust mite induced nasal inflammation (allergic rhinitis), with or without eye inflammation (conjunctivitis). Odactra is an allergen extract immunotherapy

    2/28/25 5:00:47 PM ET
    $TNDM
    Medical/Dental Instruments
    Health Care

    November 7, 2023 - FDA Roundup: November 7, 2023

    For Immediate Release: November 07, 2023 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  On Monday, the FDA issued a Safety Communication warning consumers, health care providers, and health care facilities not to use recalled saline (0.9% sodium chloride) and sterile water medical products manufactured by Nurse Assist, LLC. On November 6, Nurse

    11/7/23 3:38:18 PM ET
    $TNDM
    Medical/Dental Instruments
    Health Care

    FDA Approval for XPHOZAH issued to ARDELYX INC

    Submission status for ARDELYX INC's drug XPHOZAH (ORIG-1) with active ingredient TENAPANOR has changed to 'Approval' on 10/17/2023. Application Category: NDA, Application Number: 213931, Application Classification: Type 10 - New Indication Submitted as Distinct NDA - Not Consolidated

    10/20/23 4:37:52 AM ET
    $ARDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALLR
    $APVO
    $ARDX
    $CRDF
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Tandem Diabetes Care upgraded by Truist with a new price target

    Truist upgraded Tandem Diabetes Care from Hold to Buy and set a new price target of $35.00

    3/19/26 8:24:11 AM ET
    $TNDM
    Medical/Dental Instruments
    Health Care

    Tandem Diabetes Care upgraded by Piper Sandler with a new price target

    Piper Sandler upgraded Tandem Diabetes Care from Neutral to Overweight and set a new price target of $33.00

    3/17/26 7:55:10 AM ET
    $TNDM
    Medical/Dental Instruments
    Health Care

    Tandem Diabetes Care upgraded by Lake Street with a new price target

    Lake Street upgraded Tandem Diabetes Care from Hold to Buy and set a new price target of $50.00

    2/23/26 8:30:19 AM ET
    $TNDM
    Medical/Dental Instruments
    Health Care

    $ALLR
    $APVO
    $ARDX
    $CRDF
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Raab Michael

    4 - ARDELYX, INC. (0001437402) (Issuer)

    3/18/26 4:42:26 PM ET
    $ARDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Novara Mark David

    4 - TANDEM DIABETES CARE INC (0001438133) (Issuer)

    3/18/26 4:06:02 PM ET
    $TNDM
    Medical/Dental Instruments
    Health Care

    Officer Hochman David P bought $42,900 worth of shares (10,000 units at $4.29), increasing direct ownership by 0.93% to 1,086,467 units (SEC Form 4)

    4 - Orchestra BioMed Holdings, Inc. (0001814114) (Issuer)

    3/16/26 4:54:18 PM ET
    $OBIO
    Medicinal Chemicals and Botanical Products
    Health Care

    $ALLR
    $APVO
    $ARDX
    $CRDF
    Leadership Updates

    Live Leadership Updates

    View All

    Cue Biopharma Appoints Industry Veteran Lucinda Warren as Chief Financial and Business Officer

    BOSTON, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ:CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of autoimmune and inflammatory diseases, today announced that Lucinda Warren, who has served as Cue Biopharma's chief business officer (CBO) since September 2024, has been appointed chief financial and business officer (CFBO) effective February 9, 2026. "The combination of Lucinda's financial and business acumen together with her extensive background makes the CFBO a key strategic partner in helping drive business growth and Company success, part

    2/12/26 8:00:00 AM ET
    $CUE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cardiff Oncology Announces Executive Leadership Changes as it Transitions to Late-Stage Clinical Development

    SAN DIEGO, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced a leadership transition designed to support the Company's next phase of growth and advancement toward late-stage development and key clinical and corporate milestones. Mani Mohindru, PhD, a member of Cardiff Oncology's Board of Directors since 2021 and a seasoned biotech executive, has been appointed interim Chief Executive Officer, effective immediately. Mark Erlander, PhD, Chief Executive Officer, and James Levine, Chief Financial Officer, have stepped down from their res

    1/27/26 7:00:00 AM ET
    $CRDF
    $CTMX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    NKGen Biotech Names Leading Dementia Expert Bruce L. Miller, M.D. to Scientific Advisory Board

    SANTA ANA, Calif., Jan. 22, 2026 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC:NKGN) ("NKGen" or the "Company"), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer ("NK") cell therapeutics, today announced the appointment of Bruce L. Miller, M.D. to its Scientific Advisory Board. Dr. Miller is internationally recognized for his leadership in Alzheimer's disease ("AD"), frontotemporal dementia ("FTD"), and other neurocognitive disorders, and brings extensive scientific and clinical expertise to the Company. Dr. Miller is the A.W. and Mary Margaret Clausen Distinguished Professor in Neurology at the U

    1/22/26 8:05:00 AM ET
    $NKGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALLR
    $APVO
    $ARDX
    $CRDF
    Financials

    Live finance-specific insights

    View All

    Cardiff Oncology Reports Full Year 2025 Results and Provides Business Update

    Reported positive update from Phase 2 CRDF-004 trial in first-line RAS-mutated mCRC, with the 30 mg onvansertib + FOLFIRI/bev arm demonstrating:• Robust ORR of 72.2% (vs 43.2% with combined SoC of FOLFOX/bev and FOLFIRI/bev)• Significant improvement in PFS over combined SoC (HR: 0.37, p<0.05) Data support selection of 30 mg onvansertib dose in combination with FOLFIRI/bev for planned registrational program; detailed data and registrational plans expected in the first half of 2026 SAN DIEGO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today an

    2/24/26 4:30:00 PM ET
    $CRDF
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Tandem Diabetes Care Announces Fourth Quarter and Full Year 2025 Financial Results and 2026 Financial Guidance

    Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a global insulin delivery and diabetes technology company, today reported its financial results for the quarter and fiscal year ended December 31, 2025 and provided its financial guidance for the year ending December 31, 2026. Fourth Quarter 2025 Financial and Strategic Highlights Achieved record quarterly sales: Worldwide sales of $290.4 million United States sales of $210.5 million Worldwide pump shipments of 38,000 United States pump shipments of 27,000 Delivered meaningful operational improvement: Record quarterly gross margin of 58% Operating income of $8.3 million, or 3% of sales Net loss of $0.6 million with posi

    2/19/26 4:05:00 PM ET
    $TNDM
    Medical/Dental Instruments
    Health Care

    Ardelyx Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

    IBSRELA revenue grew 73% in 2025 to $274.2 million and total revenues reached $407.3 million Patient-first XPHOZAH strategy preserved access and drove growth in total dispenses Development programs for new IBSRELA indication and next-generation NHE3 inhibitor launched Company is well capitalized to meet current business objectives Conference call scheduled for 4:30 PM Eastern Time WALTHAM, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs, today reported financial results for the fourth quarter and full year

    2/19/26 4:01:00 PM ET
    $ARDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALLR
    $APVO
    $ARDX
    $CRDF
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Indaptus Therapeutics Inc.

    SC 13D/A - Indaptus Therapeutics, Inc. (0001857044) (Subject)

    11/26/24 4:11:08 PM ET
    $INDP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Tandem Diabetes Care Inc.

    SC 13G/A - TANDEM DIABETES CARE INC (0001438133) (Subject)

    11/14/24 4:15:44 PM ET
    $TNDM
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Ardelyx Inc.

    SC 13G/A - ARDELYX, INC. (0001437402) (Subject)

    11/14/24 4:08:33 PM ET
    $ARDX
    Biotechnology: Pharmaceutical Preparations
    Health Care